Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dipyridamole Induced Ischemia and Biomarkers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03688815
Recruitment Status : Completed
First Posted : September 28, 2018
Last Update Posted : September 28, 2018
Sponsor:
Information provided by (Responsible Party):
Tihamér Molnár, University of Pecs

Brief Summary:
Analysis of certain biomarkers and transient myocardial perfusion deficit revealed by myocardial perfusion scintigraphy.

Condition or disease Intervention/treatment
Ischemic Heart Disease Ischemic Attack Diagnostic Test: myocardial perfusion scintigraphy

Detailed Description:
The prospectively enrolled patients were followed up to 5 years. Adverse major events (MI, stroke, death) suffered during follow-up were retrospectively analysed.

Layout table for study information
Study Type : Observational
Actual Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Relationship Between the L-arginine Pathway Metabolites and Dipyridamole Stress Induced Transient Myocardial Ischaemia
Actual Study Start Date : January 1, 2009
Actual Primary Completion Date : January 1, 2010
Actual Study Completion Date : January 1, 2017

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Patients with ischemic heart disease
Patients with ischemic heart disease scheduled for myocardial perfusion scintigraphy were enrolled. Biomarkers were analysed form periferal blood. Patients outcome data were followed up to 5 years.
Diagnostic Test: myocardial perfusion scintigraphy
Myocardial perfusion scintigraphy as it is described in the international literature.




Primary Outcome Measures :
  1. Myocardial perfusion abnormality [ Time Frame: 5 year follow-up after MPS ]
    Myocardial perfusion was quantified based on myocardial perfusion scintigraphy (MPS).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Consecutive patients with IHD were enrolled.
Criteria

Inclusion Criteria: 1. written informed consent. 2. clinical diagnosis of ischemic heart disease (IHD) -

Exclusion Criteria: 1. refused written informed consent. 2. lost data during follow-up

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03688815


Locations
Layout table for location information
Hungary
University of Pecs
Pécs, Baranya, Hungary, 7624
Sponsors and Collaborators
University of Pecs
Investigators
Layout table for investigator information
Principal Investigator: Tihamer Molnar, MD University of Pecs
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Tihamér Molnár, Associate professor, University of Pecs
ClinicalTrials.gov Identifier: NCT03688815    
Other Study ID Numbers: PTE3950
First Posted: September 28, 2018    Key Record Dates
Last Update Posted: September 28, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: IPD sharing plan: publication of data in a peer-reviewed journal

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Myocardial Ischemia
Coronary Artery Disease
Ischemia
Pathologic Processes
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arteriosclerosis
Arterial Occlusive Diseases